Dr. Chitnis has served as the Principal investigator of several clinical trials, including the PARADIGMS trial of fingolimod in pediatric MS, the TERIKIDS trial evaluating teriflunomide in pediatric MS, and several early stage trials for novel molecules for the treatment of MS and autoimmune disorders in adults.

Current & Recently Completed Trials:

A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon Beta-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase (PARADIGMS)

A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension (TERIKIDS)

A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patientreported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy to ofatumumab (Phase IIIb)


A Phase I Study of the Safety, Tolerability and Immune Effects of the Nasal Anti-CD3 Monoclonal Antibody Foralumab in Healthy Human Volunteers



A Phase I Single-Ascending Dose Study of the Safety and Immune Effects Tolerability of the Oral Anti-CD3 Monoclonal Antibody Foralumab in Healthy Human Volunteers